Indeed a recent study in metastatic renal cell carcinoma has shown that patients with thrombocytosis had a higher risk to present a primary refractoriness to anti-VEGF treatments (odds ratio = 1.7, P = 0.0068) than patients with normal platelets [29]. The gene discussed is VEGFA; the disease is thrombocytosis disease.